Delisting riskPopularity #4,715
MSLE · NASDAQ · Biotechnology

Satellos Bioscience (MSLE)

Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.

$8.87
After hours−0.13 (−1.44%)
At close$9.00(−1.96%)